Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2023-03-16 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Tislelizumab, Vitamin E |
Tags
MSS/ MMRp
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | Phase
Phase 2, Phase 3
|
Date Added 2023-03-15 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05768503 |
TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | Phase
Phase 3
|
Date Added 2023-03-14 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Control Rx, Experimental drug |
Tags
MSS/ MMRp
|
| NCT ID NCT05759728 |
TitleA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2023-03-08 |
Location
Australia
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05743036 |
TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-02-24 |
Location
California, United States
Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Terminated
|
Drugs
cetuximab, encorafenib, ZN-c3 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Phase
Phase 2
|
Date Added 2023-02-17 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT05726864 |
TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-02-14 |
Location
Arizona, United States
California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ELI-002 7P |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05722327 |
TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-02-10 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, Irinotecan, MRTX849 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05714553 |
TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Phase
Phase 1, Phase 2
|
Date Added 2023-02-06 |
Location
United Kingdom
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Terminated
|
Drugs
Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05684211 |
TitleA Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-01-13 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Ametumumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
